196 related articles for article (PubMed ID: 10487453)
1. A double-blind randomized clinical trial of a topical herbal extract (Z-HE) vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in Iran.
Zerehsaz F; Salmanpour R; Handjani F; Ardehali S; Panjehshahin MR; Tabei SZ; Tabatabaee HR
Int J Dermatol; 1999 Aug; 38(8):610-2. PubMed ID: 10487453
[No Abstract] [Full Text] [Related]
2. Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis.
Mujtaba G; Khalid M
Int J Dermatol; 1999 Aug; 38(8):607-9. PubMed ID: 10487452
[No Abstract] [Full Text] [Related]
3. A double-blind randomized clinical trial of a topical herbal extract (Z-he) vs. systemic meglumine antimonate.
Momeni AZ; Aminjavaheri M
Int J Dermatol; 2000 Nov; 39(11):880. PubMed ID: 11123462
[No Abstract] [Full Text] [Related]
4. Intralesional treatment of cutaneous leishmaniasis with meglumine antimoniate.
Aste N; Pau M; Ferreli C; Biggio P
Br J Dermatol; 1998 Feb; 138(2):370-1. PubMed ID: 9602904
[No Abstract] [Full Text] [Related]
5. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate.
Faghihi G; Tavakoli-kia R
Clin Exp Dermatol; 2003 Jan; 28(1):13-6. PubMed ID: 12558620
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
Miranda-Verástegui C; Llanos-Cuentas A; Arévalo I; Ward BJ; Matlashewski G
Clin Infect Dis; 2005 May; 40(10):1395-403. PubMed ID: 15844060
[TBL] [Abstract][Full Text] [Related]
7. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis.
López L; Robayo M; Vargas M; Vélez ID
Trials; 2012 May; 13():58. PubMed ID: 22594858
[TBL] [Abstract][Full Text] [Related]
8. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
[TBL] [Abstract][Full Text] [Related]
9. Lack of efficacy of liposomal glucantime in the treatment of cutaneous leishmaniasis.
Ghoyonlo VM; Jafari MR; Yazdanpanah MJ; Esmaili H; Noori S; Kiafar B
Indian J Dermatol Venereol Leprol; 2016; 82(3):347-9. PubMed ID: 27088953
[No Abstract] [Full Text] [Related]
10. Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis.
Duque MC; Vasconcellos ÉC; Pimentel MI; Lyra MR; Pacheco SJ; Marzochi MC; Rosalino CM; Schubach AO
Rev Soc Bras Med Trop; 2016; 49(6):774-776. PubMed ID: 28001228
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
Armijos RX; Weigel MM; Calvopiña M; Mancheno M; Rodriguez R
Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664
[TBL] [Abstract][Full Text] [Related]
12. Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy.
Shamsi Meymandi S; Javadi A; Dabiri S; Shamsi Meymandi M; Nadji M
Arch Iran Med; 2011 Jul; 14(4):238-43. PubMed ID: 21726098
[TBL] [Abstract][Full Text] [Related]
13. [Antimonial treatments of leishmaniasis].
Oliveira Neto MP
Rev Soc Bras Med Trop; 2005; 38(5):446. PubMed ID: 16172767
[No Abstract] [Full Text] [Related]
14. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
Moosavi Z; Nakhli A; Rassaii S
Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
[No Abstract] [Full Text] [Related]
15. A comparative study between the efficacy of oral cimetidine and low-dose systemic meglumine antimoniate (MA) with a standard dose of systemic MA in the treatment of cutaneous leishmaniasis.
Shanehsaz SM; Ishkhanian S
Int J Dermatol; 2015 Jul; 54(7):834-8. PubMed ID: 26108265
[TBL] [Abstract][Full Text] [Related]
16. Successful therapeutic response of resistant cases of mucocutaneous leishmaniasis to a very low dose of antimony.
de Oliveira-Neto MP; Mattos Mda S
Rev Soc Bras Med Trop; 2006; 39(4):376-8. PubMed ID: 17119754
[TBL] [Abstract][Full Text] [Related]
17. Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities.
Pimentel MIF; Vasconcellos ÉCFE; Ribeiro CO; Lyra MR; Saheki MN; Salgueiro MM; Antonio LF; Schubach AO
Rev Soc Bras Med Trop; 2017; 50(2):269-272. PubMed ID: 28562769
[TBL] [Abstract][Full Text] [Related]
18. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.
Rubiano LC; Miranda MC; Muvdi Arenas S; Montero LM; Rodríguez-Barraquer I; Garcerant D; Prager M; Osorio L; Rojas MX; Pérez M; Nicholls RS; Gore Saravia N
J Infect Dis; 2012 Feb; 205(4):684-92. PubMed ID: 22238470
[TBL] [Abstract][Full Text] [Related]
19. [Side effects of meglumine antimoniate in cutaneous leishmaniasis: 15 cases].
Ezzine Sebai N; Mrabet N; Khaled A; Zeglaoui F; Kharfi M; Fazaa B; Kamoun MR
Tunis Med; 2010 Jan; 88(1):9-11. PubMed ID: 20415206
[TBL] [Abstract][Full Text] [Related]
20. Comparison of intralesionally injected zinc sulfate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis.
Iraji F; Vali A; Asilian A; Shahtalebi MA; Momeni AZ
Dermatology; 2004; 209(1):46-9. PubMed ID: 15237267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
